

Zimam Mahmud

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11040608/publications.pdf>

Version: 2024-02-01

9
papers

171
citations

1307594
7
h-index

1474206
9
g-index

9
all docs

9
docs citations

9
times ranked

344
citing authors

#	ARTICLE	IF	CITATIONS
1	Thienopyrimidinone Based Sirtuin-2 (SIRT2)-Selective Inhibitors Bind in the Ligand Induced Selectivity Pocket. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 1928-1945.	6.4	49
2	EP300 and SIRT1/6 Co-Regulate Lapatinib Sensitivity Via Modulating FOXO3-Acetylation and Activity in Breast Cancer. <i>Cancers</i> , 2019, 11, 1067.	3.7	29
3	Regulation of PERK expression by FOXO3: a vulnerability of drug-resistant cancer cells. <i>Oncogene</i> , 2019, 38, 6382-6398.	5.9	28
4	Unravelling the role of fatty acid metabolism in cancer through the FOXO3-FOXM1 axis. <i>Molecular and Cellular Endocrinology</i> , 2018, 462, 82-92.	3.2	22
5	Lapatinib sensitivity in nasopharyngeal carcinoma is modulated by SIRT2-mediated FOXO3 deacetylation. <i>BMC Cancer</i> , 2019, 19, 1106.	2.6	13
6	FOXA1 is a determinant of drug resistance in breast cancer cells. <i>Breast Cancer Research and Treatment</i> , 2021, 186, 317-326.	2.5	12
7	Reciprocal regulation between GCN2 (eIF2AK4) and PERK (eIF2AK3) through the JNK-FOXO3 axis to modulate cancer drug resistance and clonal survival. <i>Molecular and Cellular Endocrinology</i> , 2020, 515, 110932.	3.2	9
8	Oncogenic EP300 can be targeted with inhibitors of aldo-keto reductases. <i>Biochemical Pharmacology</i> , 2019, 163, 391-403.	4.4	5
9	Characterization of FOXO Acetylation. <i>Methods in Molecular Biology</i> , 2019, 1890, 77-90.	0.9	4